SomatostatinのInsulinおよびGlucagon分泌抑制作用に関する実験的研究:-Somatostatin投与時の末梢血IRI及びIRGの変化について-

概要

論文の詳細を見る
This study was performed in order to investigate the suppressive effect of somatostatin on the endocrine pancreas in Ketalar-anesthetized dogs. In the 1st group, somatostatin was administered (250μg in one shot followed by infusion for 30 minutes at the rate of 0.8μg/kg/min), the blood sugar level declined about 20mg/dl at 20 minutes. Plasma insulin (IRI) decreased to 10±3μU/ml at 3 minutes from 15±3μU/ml, but it was not significant, and plasma glucagon (IRG) to 23±5pg/ml at 3 minutes from 72±6pg/ml. Both values recovered to the basal value at 10 minutes after the termination of infusion. In the 2nd group, tolbutamide (i.v. 1.0g) was administered with somatostatin in the same manner as described above, the blood sugar level declined about 10mg/dl at 1 minute, while IRI decreased a little, but it was not significant. On the other hand, in the control, the blood sugar level declined markedly with a rise of IRI following tolbutamide administration. IRG changed a little after tolbutamide administration alone, but together with somatostatin IRG decreased to 23±7pg/ml at 15 minutes from 80±6pg/ml. In the 3rd group, both glucose and somatostatin were infused at the rate of 130mg/kg/ min and 1.6μg/kg/min, respectively, for 15 minutes after the initial bolus administration of somatostatin. The blood sugar level increased markedly to 1460±86mg/dl at 15 minutes, but IRI decreased a little, while IRI increased markedly in the control with glucose alone. In the 4th group, hydrocortisone was administered with glucose and somatostatin. No increase of IRI was observed. In the 5th group, arginine was administered at the rate of 130mg/kg/min together with somatostatin (1.6μg/kg/min), the blood sugar level declined about 30mg/dl at 15 minutes, while IRI decreased a little and IRG decreased to 28±5pg/ml from 82±13pg/ml. On the other hand, in the control with arginine alone, both IRI and IRG increased markedly. These results demonstrate that somatostatin suppresses the endocrine pancreatic function when the stimulator was administered as well as in the fasting state.
日本内分泌学会の論文

SomatostatinのInsulinおよびGlucagon分泌抑制作用に関する実験的研究:-Somatostatin投与時の末梢血IRI及びIRGの変化について-

スポンサーリンク

概要

著者

関連論文

スポンサーリンク